John P. Hamill - 28 Mar 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SrVP/CFO/Prin Fin & Acct Ofcr
Signature
/s/ John Hamill
Issuer symbol
APRE
Transactions as of
28 Mar 2024
Net transactions value
$0
Form type
4
Filing time
28 Mar 2024, 17:59:46 UTC
Previous filing
14 Mar 2024
Next filing
15 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +3,365 +22% $0.000000 18,868 28 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +13,460 $0.000000 13,460 28 Mar 2024 Common Stock 13,460 $6.69 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.